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Objective: Overexpression of METCAM/MUC18, an immunoglobulin-like cell-adhesion molecule, pro-
motes tumorigenesis and progression of human breast cancer cells. We also observed an intriguing
phenomenon that a high-expressing SK-BR-3 clone manifested a transient tumor suppression effect
in vivo. The purpose of this study was to understand if this was caused by clonal variation, METCAM/
MUC18-dosage effect, or the number of cells injected.
Materials and Methods: Several G418-resistant clones of SK-BR-3, expressing different levels of METCAM/
MUC18, were obtained for testing effects of human METCAM/MUC18 on in vitro motility, invasiveness,
and anchorage-independent colony formation (in vitro tumorigenicity) and in vivo tumorigenesis in fe-
male Balb/C athymic nude mice. Tumor sections were made for histology and immunohistochemistry
analyses, and tumor lysates for Western blot analysis to determine the effects of human METCAM/MUC18
expression on levels of various downstream effectors.
Results: METCAM/MUC18 promoted in vitro motility, invasiveness, and in vitro tumorigenicity of SK-BR-
3 cells in a dosage-speciﬁc manner. Overexpression of METCAM/MUC18 could promote in vivo tumori-
genesis of SK-BR-3 cells even when one tenth of the previously used cell number (5  105) was injected
and in vivo tumorigenesis of SK-BR-3 cells was directly proportional to the dosage of the protein. The
previously observed transient tumor suppression effect from the same clone was no longer observed. The
downstream effector, such as phospho-AKT/AKT ratio, was elevated in the tumors.
Conclusion: Transient suppression observed previously in the clone was caused by injection of a high cell
number (2  106e5  106). METCAM/MUC18 positively promotes tumorigenesis of SK-BR-3 cells by
increasing the survival and proliferation pathway.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Breast cancer is still the most prevalent and deadly cancer in
womenworldwide, as well as in Taiwan [1]. The cause of death from
recurrent breast cancer is distant metastasis. After many years of
extensive studies, the mechanism and biology of breast cancer tu-
mor formation and metastasis is still poorly understood [2]. MET-
CAM/MUC18, an immunoglobulin (Ig)-like cell-adhesion molecule,
plays an important role in promoting angiogenesis, tumorigenesis,
and metastasis in melanoma and prostate cancer [3e12]. Likewise,
overexpression of METCAM/MUC18 promotes tumorigenesis andechnology, 200, ChungPei Rd,
cu.edu.tw (G.-J. Wu).
bstetrics & Gynecology. Publishedprogression of human breast cancer cells [13e15].We also observed
an intriguing phenomenon that a high-expressing SK-BR-3 clone
manifested a transient tumor suppression effect in vivo, but not the
other high-expressing clone [14]. The purpose of this study was to
further understand if this was due to clonal variation, METCAM/
MUC18-dosage effect, or the number of cells injected.
For comparison, several G418-resistant (G418R) clones of SK-BR-
3, expressing different levels ofMETCAM/MUC18, were obtained for
re-examination in animal tests. Two million cells per clone were
injected in athymic mice from the National Laboratory Animal
Center (Taipei, Taiwan), and tumorigenicity was determined. We
found that suppressionwas again observed for one high-expressing
clone and two moderate-expressing clones but not the low-
expressing clone. These G418R-clones of SK-BR-3, expressing
different levels of METCAM/MUC18, were used for testing effects ofby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Figure 1. Expression of METCAM/MUC18 in G418R-SK-BR-3 clones. Human METCAM/
MUC18 expression in lysates prepared from various clones/cells, 5 mg proteins per lane,
was determined by western blot analysis. Cell lysates from SK-Mel-28 (Lane 1) and that
from the parental SK-BR-3 (Lane 2) were used as a positive and a negative controls,
respectively. METCAM/MUC18 expression in cell lysates from seven different clones
(2F-1, 2F-2, 2F-3, 2F-7N, 2F-18N, 2F-20N, and 2F-22N) and two pooled clones (pooled
2F and pooled 3F) of SK-BR-3 is shown in Lanes 3e11. The number under each lane
indicates the relative level of METCAMMUC18 in each cell line/clone, assuming that in
SK-Mel-28 as 100%. a-Actin was the loading control.
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tumorigenesis in female athymic nude mice (Balb/cAnN.Cg-
Foxnlnu/CrlNarl) from the National laboratory Animal Center (Tai-
pei, Taiwan). Tumor sections were taken for histological and
immunohistochemical analyses and tumor lysates for Western blot
analysis to determine the effects of huMETCAM/MUC18 expression
on levels of various downstream effectors. We observed that MET-
CAM/MUC18 promoted in vitro motility and invasiveness in a
dosage-speciﬁc manner. The extent of formation of anchorage-
independent colony (in vitro tumorigenicity) of SK-BR-3 cells was
directly proportional to the dosage of the protein. Overexpression of
METCAM/MUC18 promoted tumorigenesis of SK-BR-3 cells when
one tenth of the previously used cell number (5 105) was injected
into female athymic nude mice. Furthermore, the extent of in vivo
tumorigenesis of SK-BR-3 cells was directly proportional to the
dosage of the protein. The transient tumor suppression effect from
the sameclone,whichwepreviouslyobserved in athymicnudemice
(Hsd: Athymic Nude-nu) from Harlan Company, Indianapolis, IN,
USA, was no longer found.
We concluded that the transient suppressive effect from the
clone was not due to clonal variation, or METCAM/MUC18-dosage
effect, or the different genetic background of the mice, but rather
to the effect of a high number of injected cells (2  106e5  106).
The downstream effector, such as the phospho-AKT/AKT ratio, was
elevated in the tumors, suggesting that METCAM/MUC18 positively
promotes tumorigenesis of SK-BR-3 cells by augmenting the sur-
vival and proliferation pathway.
Materials and methods
Cell lines and culture conditions
Human breast cancer cell line SK-BR3 from the American Type
Culture Collection (ATCC) was grown andmaintained in McCoy's 5A
medium with 10% fetal bovine serum (FBS) as previously described
[14]. A human melanoma cell line, SK-Mel-28, and three human
prostate cancer cell lines, DU145, PC-3, and LNCaP, from ATCC were
grownandmaintained aspreviously described [14]. All G418R SK-BR-
3 clones were grown in the same medium of parental SK-BR-3 cells
(McCoy's 5A medium supplemented with 10% FBS plus 0.8 mg/mL
G418 (Cellgro/MediaTech (Manassas, VA, USA) and Hyclone (Logan,
UT, USA)) in a humidiﬁed 37C incubator with 5% CO2.
Lipofection of SK-BR-3 cells and selection for METCAM/MUC18-
expressing G418R-clones
Lipofection was carried out according to a published procedure
[13,14], except that FuGene HD (Roche, Indianapolis, IN, USA) was
used as the transfecting agent and 0.8 mg/mL G418 (active compo-
nent ~75%) was added to the growth medium after transfection.
G418R clones were transferred and expanded sequentially from 24-
well to six-well culture plates. Cell lysates of each clone were made
from each well of six-well plates, boiled, and kept frozen at 20C.
The METCAM/MUC18-positive clones were further expanded, pro-
cessed, and frozen in liquid nitrogen for preservation as stocks. After
24 colonies were picked, the remaining majority of colonies in the
60-mm plates were trypsinized, mixed, and seeded to two T-25
ﬂasks. Cells grown in one ﬂaskwere expanded,made into stock, and
designated as a pooled clone; those in another ﬂask weremade into
Western blot lysates and designated as a pooled clone lysate.
Cell motility assay
A cell motility assay was carried out according to a published
method [16] with minor modiﬁcations [5e8,13,14]. After 18 hours,cells migrating to the bottom wells were detached with trypsin
treatment, concentrated by centrifugation, and counted with a
hemocytometer. The experiments were repeated three times and
means and standard deviations of triplicate values were indicated.
Cell invasiveness assay
A cell invasiveness assay was carried out according to a pub-
lished method [16] with minor modiﬁcations [5e8,13,14]. All pro-
cedures were similar to cell motility assays except that before
seeding cells to the top wells, the porous polycarbonate membrane
(pore size 8 mm) at the bottom of each top well was coated with
70 mg or 140 mg of the diluted Matrigel (growth-factors-reduced
and phenol-red-free grade; Cultrex, Trevigen, Gaithersburgh, MD,
USA, cat. # 3431-005-01, 12.8 mg/mL diluted to 1 mg/mL). After
24 hours, cells migrating to the bottom well were processed and
counted. Means and standard deviations of triplicate values were
indicated.
Anchorage-independent colony-formation assay
The published procedures [17] were followed with slight mod-
iﬁcations [13,14]. The number of colonies (20e50 cells per colony)
was counted after 14 days in a humidiﬁed 37C CO2 incubator.
Determination of tumorigenicity of SK-BR-3 clones/cells in athymic
nude mice
All animal tests were approved by the Institutional Animal Care
andUse Committee (IACUC)with an approval #10012 at Chung Yuan
Christian University, Taoyuan City, Taiwan. The guidelines of IACUC
were strictly followed for the animal studies. Five 7-week-old female
Balb/cAnN.Cg-Foxnlnu/CrlNarl athymic nudemice from theNational
Laboratory Animal Center were used for the subcutaneous injection
of cells from each clone. A single cell suspension from monolayer
cultures of SK-BR-3 cells of clones 2F-2 (p28), 2F-3 clone (p28), 2F-7N
(p33), 2F-18N (p32), 2F-19N (p20), 2F-20N (p36), 2F-22N (p36), or
Figure 2. Effects of METCAM/MUC18 expression on in vitromotility. (A) Motility of SK-BR-3 clones of 2F-2, 2F-3, 2F-18N, 2F-19N, and 3F, and (B) that of 2F-7N, 2F-19N, 2F-20N, 2F-
22N, and 3F clones were determined in the presence of 75e150 mg/mL of anti-human METCAM/MUC18 antibody (open columns) or control chicken immunoglobulin Y (ﬁlled
columns), as indicated. Means and standard deviations of triplicate values of motility tests are indicated. The p values were determined by analyzing two sets of data with the
Student t test by using one-tailed distribution-type 1 method.
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trypsin, washed with phosphate-buffered saline, and 2  106 or
5  105 cells were resuspended in cold 0.05 mL cold McCoy's 5A
medium without FBS, mixed with an equal volume of
15.44e15.95 mg/mL Matrigel (Cultrex; Trevigen) [18], and subcuta-
neously injected with a gauge #301/2G needle under the left third
nipple. After injection, the size of the tumor was measured with a
digital caliper every week until the endpoint of the experiment. Tu-
mor volume was calculated by using the ellipsoid formula V ¼ p/6
(d1 d2)3/2 (mm)3 [16]. At the endpoint (86 days), mice were killed
and tumors from each mouse were excised, weighed, and a portion
was used for making cell lysates for Western blot analysis [19] to
determine the levels of METCAM/MUC18 and its downstream ef-
fectors, such as B-cell lymphoma 2 (Bcl2), Bcl-2 associated X protein
(Bax), poly (ADP-ribose) polymerase (PARP), phospho-AKT (phos-
phorylated AKT)/pan AKT (all three AKTs), vascular endothelial
growth factor (VEGF), VEGF receptor 2 (VEGFR2), lactatedehydrogenase A (LDH-A), that may affect the process of tumori-
genesis. The rest of the tumor was ﬁxed in formaldehyde (Fisher,
Waltham, MA, USA), paraﬁnized, and sectioned for histology and
immunohistochemical staining.
Western blot analysis
Cell and tumor lysates were prepared by adding a Western blot
lysis buffer containing anti-proteolysis cocktails as previously
described [5e8,13,14]. The protein concentration of each lysate
was determined and veriﬁed by gel electrophoresis and staining as
previously described [5e8,13,14]. Western blot analysis was car-
ried out as previously described [5e8,13,14]. Our chicken anti-
huMETCAM/MUC18 IgY [5,20] (1/300 dilutions) was used as the
primary antibody and the alkaline phosphatase (AP)-conjugated
rabbit anti-chicken IgY (AP162A; Chemicon, Dublin, OH, USA) as
the secondary antibody (1/2000 dilution) to detect huMETCAM/
Figure 3. Effects of METCAM/MUC18 expression on in vitro invasiveness. (A) Invasiveness of the SK-BR-3 clones of 2F-2, 2F-3, 2F-18N, and 3F, and (B) that of 2F-1, 2F-7N, 2F-19N, 2F-
20N, 2F-22N, and 3F clones were also determined in the presence of 75e150 mg/mL anti-huMETCAM/MUC18 antibody (open columns) or control chicken immunoglobulin Y (ﬁlled
columns), as indicated. Means and standard deviations of six repeated values of invasiveness tests are indicated. The p values were determined by analyzing two sets of data with
the Student t test by using one-tailed distribution-type 1 method.
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primary antibodies to detect expression levels of Bcl2 (N-19, SC-
492; Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bax (N-20,
SC-493; Santa Cruz Biotechnology), VEGF (SC-152; Santa Cruz
Biotechnology), and LDH-A [21]. A rabbit monoclonal antibody
was used to detect the expression level of VEGFR2 (53B11, 2479;
Cell Signaling Technology, Danvers, MA, USA). Primary antibodies
for detecting housekeeping genes actin, GAPDH, and b-tubulin
were goat polyclonal antibody (SC-1615; Santa Cruz Biotech-
nology), goat polyclonal antibody (SC-20358; Santa Cruz Biotech-
nology) and rabbit polyclonal antibody (SC-9104; Santa Cruz
Biotechnology), respectively, and secondary antibodies were rabbit
anti-goat (AP106 A; Chemicon) and goat anti-rabbit (AP132A;
Chemicon), respectively. The substrates BCIP (5-bromo-4-chloro-
3-indolyl-phosphate)/NBT (nitro blue tetrazolium) (S3771; Prom-
ega, Madison, WI, USA) were used for color development. The
image of the speciﬁc protein band corresponding to METCAM/
MUC18 or other proteins on the nitrocellulose membrane was
scanned with an Epson Scanner model 1260 (Epson, Long Beach,
CA, USA) and its intensity was quantitatively determined by a NIHsoftware program (Image J version 1.31, National Institutes of
Health, Bethesda, MD, USA).
Histology and immunohistochemistry staining of tumor tissue
sections
Parafﬁn-embedded tissue sections (5 mm) were used. A tissue
section of the subcutaneous tumor derived from the LNCaP-
expressing clone, LNS239 [6,7,10], was used as a positive external
control for the immunohistochemical staining. Tissue sections were
deparafﬁnized, rehydrated with graded alcohol and phosphate-
buffered saline, and used for histological staining [22] and immu-
nohistochemical analyses as previously described [6,7,13,14,23].
Dilutions (1/200 to 1/300) of the chicken anti-huMETCAM/MUC18
IgY were used as the primary antibody and a 1/250 dilution of the
biotinylated anti-chicken IgY antibodies (G2891; Promega) as the
secondary antibody [6e8,10,13,14]. A streptavidin-conjugated
horseradish peroxidase complex (LSAAB-2 system; Dako, via Real
Carpinteria, CA, USA) and diaminobenzidine were used for color
development. Hematoxylinwas used for counter staining. Negative
Figure 4. Formation of anchorage-independent colony formation in soft agar. Quantitative results of the abilities of ﬁve SK-BR-3 clones, the 2F-20N, 2F-22N, 2F-7N and 2F-19N
clones and the pooled empty vector 3F clone, in forming anchorage-independent colonies in soft agar are shown in (A) and (B). The mean values and standard deviations from the
colony numbers in at least four wells are shown. The p value was determined by analyzing the data with the Student t test by using the one-tailed distribution-type 1 method.
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the control isotype chicken IgY.
Statistical analysis
The Student t test was used to analyze the statistical signiﬁcance
of the data in all ﬁgures. Two corresponding sets of data were
considered signiﬁcantly different if the p value was < 0.05.
Results
METCAM/MUC18 expression in G418R-clones derived from SK-BR-
3 cells
Previously, we observed an intriguing phenomenon that a high-
expressing SK-BR-3 clone manifested transient tumor suppressionin vivo, but not the other high-expressing clone [14]. To understand
if this was due to clonal variation, dosage effect, or simply an
artifact, we obtained several G418-resistant clones of SK-BR-3 that
expressed different levels (24e84%) of METCAM/MUC18 and
compared them to the two previous clones, 2F-2 (118%) and 2F-3
(94%), as shown in Figure 1.METCAM/MUC18 expression increased in vitro motility and
invasiveness of SK-BR-3 cells
Motility of SK-BR-3 cells was proportional to expression of
METCAM/MUC18 in the clones (Figure 2A). Invasiveness of SK-BR-
3 cells was proportional to expression of METCAM/MUC18 in the
clones (Figure 3A). These cellular behaviors were reduced by the
presence of anti-METCAM/MUC18 (Figures 2B and 3B). We
Figure 5. Effects of METCAM/MUC18 expression on (A) in vivo tumorigenesis, (B) tumor-take, (C) tumorigenicity, and (D) mean ﬁnal tumor weights of SK-BR-3 clones/cells in female athymic nude mice. All the mice were injected with
2  106 cells per mouse. (A) The left-most panel shows the mice bearing tumors from the 2F-20N clone; the middle left panel the mice bearing tumors from the 2F-22N clone; the middle central panel the mice bearing tumors from the
2F-7N clone; the middle right panel the mice bearing tumors from the 2F-19N clone; and the right-most panel the mice bearing tumors from the pooled 3F clone. The actual size of excised tumor is shown under each mouse. The bar
shows the scale of 1 cm. (B) Tumor-take shows number of mice bearing tumors for each of the four clones at the end point of the experiment. (C) Tumorigenicity of the ﬁve SK-BR-3 clones in athymic nude mice is shown by plotting
mean tumor volumes/weights versus days after injection. The p values were determined by analyzing all the data with the Student t test. The p values between tumor volumes through the time course of one SK-BR-3 clone (2F-20N),
which expressed a high level of METCAM/MUC18, and two SK-BR-3 clones (2F-22N and 2F-7N), which expressed a moderate level of METCAM/MUC18, and that of the vector control SK-BR-3 clone (3F) were > 0.05. This indicates that
the differences among the three sets of data were not signiﬁcant. The p value between tumor volumes through the time course of the 2F-19N clone, which expressed a low level of METCAM/MUC18, but still was slightly higher than that
of the vector control clone (as shown in Figure 7), and that of the 3F clone was 0.08, indicating that the difference between the two sets of data may be statistically signiﬁcant. (D) The mean ﬁnal tumor weights of these four clones in
athymic nude mice were compared at the endpoint. The mean ﬁnal tumor weights from the 2F-20N, 2F-22N, and 2F-7N clones were not signiﬁcantly heavier than the mean tumor weight from ﬁve mice of the vector control clone, 3F,
since the overall p value analyzed by the Student t test was > 0.05. The mean ﬁnal tumor weight from the 2F-19N clone was signiﬁcantly heavier than the mean tumor weights from ﬁve mice of the 2F-20N, 2F-22N, 2F-7N, and the
vector control clone, 3F, since the overall p values analyzed by the Student t test were < 0.03.
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Figure 6. Effects of METCAM/MUC18 expression on (A) in vivo tumorigenesis, (B) tumor-take, (C) tumorigenicity, and (D) mean ﬁnal tumor weights of SK-BR-3 clones/cells in female
athymic nude mice. All the mice were injected with 5  105 cells per mouse. (A) The left-most panel shows the mice bearing tumors from the 2F-2 clone; the middle left panel the
mice bearing tumors from the 2F-3 clone; the middle right panel the mice bearing tumors from the 2F-18N clone; and the right-most panel the mice bearing tumors from the
pooled 3F clone. The actual size of excised tumor is shown under each mouse. The bar shows the scale of 1 cm. (B) Tumor-take shows number of mice bearing tumors for each of the
four clones at the endpoint of the experiment. (C) Tumorigenicity of the four SK-BR-3 clones in athymic nude mice is shown by plotting mean tumor volumes/weights versus days
after injection. The p values were determined by analyzing all the data with the Student t test. The p value between tumor volumes through the time course of the three SK-BR-3
clones that expressed high level of METCAM/MUC18 (2F-2, 2F-3, and 2F-18N) and that of the vector control SK-BR-3 clone (3F) was < 0.01. The p value between tumor volumes of
the 2F-2 clone and that of the 3F clone was < 0.001. The p value between tumor volumes of the 2F-3 clone and that the 3F clone was 0.01. The p value between tumor volumes of the
2F-18N clone and that the 3F clone was 0.002. This indicates that the differences among all four sets of data were statistically signiﬁcant. (D) The mean ﬁnal tumor weights of these
four clones in athymic nude mice were compared at the endpoint. Both the mean ﬁnal tumor weights from ﬁve mice each of the 2F-2 and 2F-3 clones were statistically signiﬁcantly
heavier than the mean tumor weight from ﬁve mice of 2F-18N and ﬁve mice of 3F clone, since the overall p value analyzed by the Student t test was 0.04.
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MUC18.
METCAM/MUC18 expression increased in vitro anchorage-
independent colony formation
Anchorage-independent colony formation in soft agar has been
successfully used to assess the tumorigenicity of cancer cells
in vitro, which has been positively correlated to in vivo tumorige-
nicity in animal models [17]. The ability of SK-BR-3 cells to form
anchorage-independent colony in soft agar was dependent upon
expression of METCAM/MUC18 (Figures 4A and 4B). We conclude
that the ability of SK-BR-3 cells to induce in vitro tumorigenicity
was dependent upon the expression levels of METCAM/MUC18.
METCAM/MUC18 expression increased tumorigenicity and ﬁnal
tumor weight of SK-BR-3 cells in athymic nude mice
To re-examine if the previously observed transient tumor sup-
pressive effect of the one high-expressing clone was reproducible
in the female athymic nude mice from National Laboratory of An-
imal Center with a genetic background (Balb/cAnN.Cg-Foxnlnu/
CrlNarl) different from those from Harlan (Hsd: athymic nude-nu),a high number of cells (2  106/mouse) from four METCAM/
MUC18-expressing clones, 2F-20N, 2F-22N, 2F-7N, and 2F-19N, and
a vector control clone (clone 3F) were injected. Figures 5A and 5B
show that tumor-take was similar in all the clones, as shown in
each mouse injected with 5  106 cells per mouse [14]. Tumor
suppression was shown in the one high-expressing clones, 2F-20N,
and two moderate-expressing clones, 2F-22N and 2F-7N, but not
the low-expressing clone, 2F-19N, which had better tumorigenicity
than all the above three clones and the vector control clone
(Figure 5C). This was further supported by the results of ﬁnal tumor
weight (Figure 5D). However, we did not keep the mice for a longer
period to examine if the tumor suppression was transient.
To examine if the previously observed transient tumor sup-
pressive effect of 2F-2, which expressed a level of METCAM/MUC18
as high as the positive control SK-Mel-28, was due to an artifact of
injecting a high number of cells, we performed the same experi-
ment by injecting the same previous three clones plus one more
high-expressing clone, 2F-18N, with 5  105 cells/mouse, which
was one tenth of the cell number previously used. Overexpression
of METCAM/MUC18 promoted tumorigenesis of SK-BR-3 cells even
when the injected cell number was one tenth (5  105) of that in
the previous experiment (Figure 6A). The tumor-take was depen-
dent upon the expression levels of METCAM/MUC18 (Figure 6B).
Figure 7. Expression of METCAM/MUC18 antigens in tumor lysates (A) and (B) quantitative results of (A), and (C) the histology and immunohistochemistry of the SK-BR-3 tumors.
(A) Expression of human (hu)METCAM/MUC18 in the tumor lysates was determined by Western blot analysis. The lysate from tissue cultured SK-BR-3-2F-2 clone (Lane 1) was used
as the positive control for comparison with those in the tumor lysates (Lanes 2e20). huMETCAM/MUC18 expression levels in two tumors from the 2F-2 clone, one tumor from the
2F-3 clone, three tumors from the 2F-19N, 2F-20N, and 2F-22N, four tumors from the 2F-7N clone, and three tumors from the pooled 3F clone are shown. b-Tubulin was the loading
control. (B) shows the quantitative results of (A). (C) Panels AeD show histology of the tumor sections from the two SK-BR-3 clones, 2F-2 and 2F-3. Panels EeL show the
immunohistochemistry of these tumor sections. Panels EeH show the anti-huMETCAM/MUC18 antibody staining of the cells in the tumor sections. A tumor section from LNCaP
clone LNS239 was used as a positive control for the immunohistochemistry (Panel E). Both tumor sections from 2F-2 (Panels F and G) showed stronger brown staining in
immunohistochemistry than that from 2F-3 (Panel H) when the antibody was added, however, the tumor section from the clone 3F only showed a weak background staining (data
not shown). Panels IeL show the corresponding negative controls, which showed no staining in the adjacent sections when no antibody or control immunoglobulin Y was added.
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(2F-2), in which the transient suppression was previously observed
when 5  106 cells were used for injection (Figure 6C). Final tumor
weight, although only about one-third of that when a high number
of cells (2 106e5 106/mouse) were injected, was proportional to
the dosage of METCAM expressed in the clones (Figure 6D). We
conclude that in vivo tumorigenesis of SK-BR-3 cells was dependent
upon the expression levels of METCAM/MUC18, thus, the previ-
ously observed transient suppression was due to the injection of a
high number of cells.
METCAM/MUC18 expressed in tumors derived from different clones
of SK-BR-3 cells
To examine if METCAM/MUC18 was not altered or modiﬁed
during tumorigenesis and the tumors were indeed from the
injected clones, Western blot analysis of the METCAM/MUC18
expressed in tumor lysates was performed. METCAM/MUC18 in
different tumors from different clones were expressed at different
levels in tumor lysates, and METCAM/MUC18 had electrophoretic
mobility similar to the positive control, as expected (Figures 7A and
7B). The level of METCAM/MUC18 was not signiﬁcantly different
among the three high-expressing clones, 2F-2, 2F-3, and 2F-22N
(Figure 7B; p ¼ 0.07). Figure 7C shows the histology and immu-
nohistochemistry of these tumors. Tumor sections induced by the
METCAM/MUC18-expressing clones, 2F-2 and 2F-3, were positively
stained with the anti-METCAM/MUC18 antibodies with a stronger
staining of the two tumor sections from 2F-2 clone than that from
2F-3 clone, as shown in panels F and G versus panel H in Figure 7C.
Thus the immunohistochemistry results (Figure 7C) were consis-
tent with the Western blot results (Figures 7A and 7B), and support
the notion that these tumors originated from the injected SK-BR-3
clones, and METCAM/MUC18 was not altered or modiﬁed during
tumorigenesis, indicating that it directly mediated the process.
Preliminary mechanisms of METCAM/MUC18-mediated
tumorigenesis of SK-BR-3 cells
HuMETCAM/MUC18 expression may increase tumorigenesis by
crosstalk with many signaling pathways that affect survival,
metabolism, and proliferation, and angiogenesis of tumor cells
[24e26]. For this purpose, expression levels of an apoptotic index,
an anti-apoptosis and survival index, phospho-AKT and pan-AKT,
an index of aerobic glycolysis, and two angiogenesis indexes in
tumors were determined (Figure 8A). After quantitative and sta-
tistical analysis, we found that levels of other parameters were not
signiﬁcantly elevated (data not shown). The ratio of phospho-AKT/
AKT, the index for the survival and proliferative pathway, was
signiﬁcantly elevated in the tumors from METCAM/MUC18-
expressing clones (Figure 8B).
Discussion
During our previous investigation of the effects of overexpression
of METCAM/MUC18, an Ig-like cell-adhesion molecule, on tumori-
genesis and progression of human breast cancer SK-BR-3 cells, we
observed fortuitously an intriguing phenomenon that a high-
expressing SK-BR-3 clone manifested transient tumor suppression
in vivo, but not another high-expressing clone [14]. This phenome-
non is intriguing in that it may reveal important mechanisms of
METCAM/MUC18-mediated progression of human breast cancer
cells, especially since one group had suggested that METCAM/
MUC18 might have a tumor suppressor role in the tumorigenesis of
one human breast cancer cell line, MCF-7 [27]. First, to re-examine if
the above phenomenon was reproducible in nude mice with adifferent genetic background, we carried out in this study similar
animal tests by injecting into each nude mouse 2  106 cells from
four METCAM/MUC18-expressing clones and one vector control
clone. We found that tumor suppression was reproducible in one
high-expressing clone and two moderate-expressing clones when
compared to the vector control clone, but not a low-expressing
clone, which appeared to have a tumor-promoting effect. However,
we did not know if this suppressive effect was transient because we
did not keep the mice for a longer period. Then, to further explore
the mechanisms of METCAM/MUC18-mediated tumorigenesis of
human breast cancer cells and to understand if the above phe-
nomenonwas due to the effect of clonal variation, METCAM/MUC18
dosage, or injecting a high number of the SK-BR-3 cells, we also
carried out the experiments reported here and showed that in vitro
motility, invasiveness, formation of anchorage-independent colonies
in soft agar (in vitro tumorigenicity) and in vivo tumorigenicity of SK-
BR-3 were dependent upon the dosage of METCAM/MUC18
expression. Furthermore, overexpression of METCAM/MUC18 could
promote tumorigenesis of SK-BR-3 cells even when the injected cell
number was one tenth of that in previous experiments. Further-
more, the extent of in vivo tumorigenesis of SK-BR-3 cells was
directly proportional to the dosage of the protein. The transient
tumor-suppressive effect previously observed from the same clone
was no longer observed. We thus conclude that the previously
observed transient tumor suppression from one clone, which
expressed 118% of METCAM/MUC18, as well as two other clones was
reproduced again in this study, andwas due to the injection of a high
cell number. However, it was not due to an effect of clonal variation,
indicating that precautions should be taken into consideration for
injecting a high cell number, which appears to be a commonpractice
in many animal studies by many research groups. The results also
clearly ruled out the possibility that METCAM/MUC18 plays a tumor
suppressor role and further supported the notion that METCAM/
MUC18 plays a positive role in the progression of human breast
cancer cells [2,13e15]. From preliminary mechanical studies, we
found that METCAM/MUC18 positively promotes the tumorigenesis
of human breast cancer SK-BR-3 cells via increasing the signal in the
survival and proliferative pathway, the phospho-AKT/AKT ratio,
which in turn increases the processes of survival and proliferation
[28]. This is consistent with the notion that METCAM/MUC18 plays a
reciprocal regulatory role with the AKT pathway in the tumorigen-
esis of human cancers [12,25,29].
We are not clear why injection of a high cell number of MET-
CAM/MUC18-expressing SK-BR-3 clones caused a transient sup-
pressive effect. Three possible interpretations are as follows. One
possibility may be that when a high number of SK-BR-3 cells were
injected, the transient suppression may have been due to the high
compactness of the cells, which is supported by the recent study of
Waclaw et al [30], who suggested that the spaces in the tumor mass
can affect the growth rate of the tumor. When tumor cells are
compacted in a tight mass, it decreases the growth rate, but when
the tumor cells are loosely packed, the growth rate increases. Thus
when a high number of cells were injected, a more tightly com-
pacted initial tumor mass might have formed that transiently
repressed tumor growth. Only after 3 weeks (or even longer), the
tumor mass was somehow loosened by the high motility of cells
(due to high expression of METCAM/MUC18). When fewer cells
were injected, a more loose tumor mass was formed and cells were
more freely mobile, thus transient suppressionwas not manifested.
Alternatively, the transient suppression may have been due to tu-
mor dormancy [31], which may be triggered by injection of a high
number of cells from clones that highly express METCAM/MUC18.
The transient dormancy may be turned on by the immediate
negative response from the host innate immune system, natural
killer (NK) cells, by a transiently dominant anti-angiogenic effect, or
Figure 8. Expression of signals downstream of METCAM/MUC18. (A) shows the summarized results of Western blot analysis of expression levels of various parameters (LDH-A,
PCNA, VEGF, VEGFR2, Bcl2, Bax, PARP, pan-AKT, Phospho-AKT (Ser473) in the SK-BR-3 tumors. Expression levels of housekeeping genes, actin and b-tubulin, were used as loading
controls. The number below each lane shows the relative intensity. The numbers between the rows of actin and b-tubulin were the average relative intensities from the two
housekeeping proteins. The quantitative results of the average relative intensity of the band corresponding to ratios of phospho-AKT/AKT in tumors are also shown in (B). The p
values between those expressed in the tumor lysates derived from human METCAM/MUC18-expressing clones with a vector control clone, 3F, are shown. Bcl2, B-cell lymphoma 2;
Bax, Bcl-2 associated X protein; PARP, poly (ADP-ribose) polymerase; VEGF, vascular endothelial growth factor; VEGFR2, VEGF receptor 2; LDH-A, lactate dehydrogenase A.
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pathway, thus, the growth was suppressed. The possibility of an
immediate negative response from the host innate immune system,
NK cells, which should be intact in athymic mice, may exist since
METCAM/MUC18 has been shown to be a marker for maturation of
mouse NK cells [32], although the effect of METCAM/MUC18
expression on the response of host NK cells to tumor cells has not
been studied. The two other mechanisms of tumor dormancy may
be supported by the results in Figure 8 that the Bax level was higher
in tumor lysates than the Bcl2 level and VEGF and VEGFR2 levels
were also low. These suppressive mechanisms may be gradually
overcome after these cells have been tolerated for  3 weeks. The
third possible interpretation may be that the tumor microenvi-
ronment needs to be conditioned ﬁrst by the METCAM/MUC18-
high expressing SK-BR-3 cells to become a favorable niche for tu-
mor growth; this favorable niche may take  3 weeks to form. The
above points to a new aspect of future research for us and the
knowledge learned may reveal a new way to control the growth of
breast cancer cells; hence the translational aspect of the current
research.
We conclude that METCAM/MUC18-induced in vitro and in vivo
tumorigenesis of SK-BR-3 cells was directly proportional to
expression of METCAM/MUC18. We also conclude that the previ-
ously observed transient tumor suppression from one clone, which
expressed 118% of METCAM/MUC18, was due to the injection of a
high cell number. Thus, it was not due to an effect of clonal varia-
tion, pointing to caution when using a high cell number for injec-
tion. METCAM/MUC18 positively promotes tumorigenesis of
human breast cancer SK-BR-3 cells via increasing the signal in
survival and proliferation pathways, such as the phospho-AKT/AKT
ratio, which in turn increases the processes of survival and
proliferation.
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